Subject: Hims + Novo Make Up, Medicare Teases a GLP-1 “Bridge,” and a New Safety Signal Gets Loud
Preview text: Telehealth access is shifting fast, Medicare is testing a short-term GLP-1 pathway, and clinicians are watching a potential bone/tendon injury signal—plus community wins you can steal today.
1) Today’s News Headlines
Telehealth access to branded GLP-1s is getting reshuffled: Novo Nordisk is bringing Ozempic and Wegovy (including oral Wegovy) onto Hims & Hers after ending a legal fight. (apnews.com)
Meanwhile, CMS posted new details on a time-limited “Medicare GLP-1 Bridge” demo running July–December 2026—hinting at where coverage debates may head next. (cms.gov)
And a large, not-yet–peer-reviewed analysis raised questions about possible bone/tendon injury risk with GLP-1 therapy—worth watching, not panicking over. (washingtonpost.com)
2) Today’s Top Stories
Novo Nordisk + Hims & Hers: From Lawsuit to Branded GLP-1 Access
Novo Nordisk is dropping its patent lawsuit against Hims & Hers and will allow Hims to offer branded Ozempic and both oral and injectable Wegovy on its platform later this month. Hims also agreed to stop advertising compounded GLP-1s on its platform/marketing. (apnews.com)
Why it matters: If you’ve been stuck in the “compounded vs. branded” maze, this signals a shift toward mainstream, FDA-approved supply channels—potentially improving consistency, but not necessarily lowering out-of-pocket costs.
Source: AP News (link) (apnews.com)
CMS Posts New Details on the “Medicare GLP-1 Bridge” (July–Dec 2026)
CMS says the Medicare GLP-1 Bridge is a short-term demonstration running July 1, 2026–December 31, 2026, intended to provide eligible Part D beneficiaries “early access to certain GLP-1 drugs” ahead of the BALANCE Model launching January 1, 2027. CMS also notes an update (posted March 9, 2026) clarifying pharmacy reimbursement and states participating manufacturers will provide eligible GLP-1 drugs at a $245 net price per monthly supply, with an eligible beneficiary $50 copay that does not count toward TrOOP. (cms.gov)
Why it matters: Coverage is a major barrier; this is one of the clearest signals yet that Medicare pathways for obesity treatment are actively being engineered—though with specific eligibility rules and time limits.
Source: CMS (link) (cms.gov)
FDA Pressure Campaign on Compounded GLP-1 Marketing Widens
Industry coverage reports FDA warning letters to telehealth firms marketing compounded GLP-1s, emphasizing that compounded products are not FDA-approved and that marketing implying approval/evaluation is a red line. The report also highlights FDA’s stance that mass-marketed compounded semaglutide/tirzepatide is not legally allowed when shortages are resolved, with some companies arguing “personalization” to justify continued compounding. (fiercepharma.com)
Why it matters: If you’re using compounded medication, this doesn’t mean “stop tomorrow,” but it does mean you should plan ahead with your prescriber/pharmacy for continuity, legitimacy, and safety.
Source: Fierce Pharma (link) (fiercepharma.com)
A New (Preliminary) Safety Signal: Bone/Tendon Injury Risk Discussion Heats Up
A Washington Post report summarizes a large study presented as an abstract (not yet peer-reviewed) suggesting GLP-1 therapy may be associated with increased risk of bone and tendon injuries and other conditions like osteoporosis and gout; the report notes key limitations (e.g., dosage/duration not captured). (washingtonpost.com)
Why it matters: GLP-1s have meaningful benefits for many people, but “effective” doesn’t mean “risk-free”—and this is your reminder to pair meds with strength training, adequate protein, and clinician follow-up.
Source: The Washington Post (link) (washingtonpost.com)
3) Deep Dive (Wednesday: Community Voices)
“The boring stuff works”: small wins that compound
In r/loseit’s SV/NSV thread (March 9, 2026), people celebrated progress that looks “unsexy” but predicts long-term success: returning to exercise after pain, needing a belt for the first time in years, hitting a multi-year low on the scale, and staying consistent for 17 weeks. (reddit.com)
What stood out (and what you can copy today):
- Come back quickly after setbacks. One user got back on their bike after a week off due to back pain—showing the skill that matters most isn’t perfection, it’s rapid re-engagement. (reddit.com)
- Track process wins, not just scale wins. “Calories to spare” by focusing on low-calorie high-volume foods is a behavior win that often leads to repeatable fat loss without white-knuckling hunger. (reddit.com)
- Celebrate the “belt moment.” Clothing fit changes are often more motivating than daily weigh-ins, and they can reflect body recomposition when the scale is noisy. (reddit.com)
Actionable mini-plan (10 minutes, today):
- Pick one “re-entry workout” you can do even on a low-energy day (10–20 minutes walking, cycling, or a short strength circuit).
- Choose one high-volume meal anchor (big salad + protein, veggie-heavy soup + lean protein, or Greek yogurt + berries + fiber topping).
- Log just one thing: either protein grams, steps, or a simple “did I eat slowly?” checkmark—your choice.
4) Quick Hits
- Hims says it will bring multiple dosages of Ozempic injections and both oral/injectable Wegovy to its platform later this month as it shifts its U.S. weight-loss strategy. (investors.hims.com)
- CMS confirms the Medicare GLP-1 Bridge is time-limited (July–Dec 2026) and separate from the Medicare Drug Price Negotiation Program timeline (MFP effective Jan 1, 2027). (cms.gov)
- FDA scrutiny of compounded GLP-1 promotion is intensifying; companies have short timelines to respond to warning letters per industry reporting. (fiercepharma.com)
- Research refresher: In the SURMOUNT-5 phase 3b trial (adults with obesity without diabetes), tirzepatide produced greater mean weight loss than semaglutide at 72 weeks (trial details below). (pubmed.ncbi.nlm.nih.gov)
- Community motivation cue: r/loseit’s daily SV/NSV thread is a goldmine for “normal-people strategies” that work. (reddit.com)
- CDC/NCHS recently released updated obesity estimate reports (useful context when you’re judging your progress against population trends, not social media extremes). (blogs.cdc.gov)
5) By The Numbers
-20.2% vs -13.7%: In SURMOUNT-5 (72 weeks), least-squares mean percent weight change was -20.2% with tirzepatide vs -13.7% with semaglutide in adults with obesity without type 2 diabetes. (pubmed.ncbi.nlm.nih.gov)
What it means: Average results favored tirzepatide in this head-to-head design, but individual response, side effects, access, and long-term adherence still decide what works best for you.
Why you should care: If your plan involves medication, this helps set realistic expectations—and underscores why lifestyle supports (protein, resistance training, sleep) are still non-negotiable.
Source: PubMed record (SURMOUNT-5) (link) (pubmed.ncbi.nlm.nih.gov)
6) Ask The Community
If you had to pick one “boring but effective” habit to lock in for the next 30 days—protein at breakfast, 8k steps, strength training 2x/week, or food logging—which would you choose, and what would make it easier this time?
7) Tomorrow’s Preview
Thursday’s Expert Insights: “I’m losing weight, but I’m scared it’ll come back”—we’ll cover what obesity medicine and behavioral science say about maintenance, plateaus, and building a relapse-proof plan (with practical scripts for your next doctor visit).